Genetic and epigenetic studies of acute myeloid leukemia and therapeutic possibilities by Mujahed, Huthayfa
From Department of Medicine
Karolinska Institutet, Stockholm, Sweden
GENETIC AND EPIGENETIC 
STUDIES OF ACUTE MYELOID 
LEUKEMIA AND THERAPEUTIC 
POSSIBILITIES
Huthayfa Mujahed
Stockholm 2020
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Arkitektkopia AB, 2020 
Cover illustration by Huthayfa Mujahed 
© Huthayfa Mujahed, 2020 
ISBN 978-91-7831-709-7
Principal Supervisor:
Professor Sören Lehmann 
Karolinska Institute 
Department of Medicine Huddinge
Co-supervisors:
Associate Professor Andreas Lennartsson 
Karolinska Institute  
Department of Biosciences and Nutrition
Associate Professor Julian Walfridsson 
Karolinska Institute  
Department of Medicine Huddinge
Assistant Professor Stefan Deneberg 
Karolinska Institute 
Department of Medicine Huddinge
Opponent:
Associate Professor Marcus Järås 
Lund University 
Department of Clinical Genetics
Examination Board:
Professor Lars-Gunnar Larsson  
Karolinska Institute 
Department of Microbiology, Tumor and 
Cell Biology
Associate Professor Linda Fogelstrand 
Göteborgs University 
Department of Laboratory Medicine
Associate Professor Ola Hermanson 
Karolinska Institute 
Department of Neuroscience
Genetic and epigenetic studies of acute 
myeloid leukemia and therapeutic 
possibilities.
THESIS FOR DOCTORAL DEGREE (Ph.D.)
Public defence at Karolinska Institute on March 27th,2020 at 09.00  
Erna Möllersalen, NEO, 5th floor, Blickagången 16, Flemingsberg 
By
Huthayfa Mujahed

To my family

ABSTRACT
Acute myeloid leukaemia (AML) is malignant tumour that forms in the bone 
marrow and arises from immature myeloid progenitors. Consequently, this leads 
to excessive accumulation of dysfunctional blast cells and lack of normal blood 
cells. The molecular and genetic heterogeneity of the disease is substantial which 
makes the disease challenging to classify and treat. Although the AML classifica-
tion is updated continuously and more data and research on AML pathophysiol-
ogy emerges, first line treatment for the vast majority of AML patients remains 
a combination of cytarabine and an anthracycline. While most patients attain a 
complete remission, the majority of AML patients relapse and develop drug resist-
ance. Recently, new drugs have been approved for the treatment of specific AML 
subtypes. However, there is need for better understanding of disease pathogenesis 
including better genetic and epigenetic risk factors in order to develop more effec-
tive treatment regimens to improve the outcome of the disease.
In Study I, we studied off-target effects of APR-246, a drug that originally was 
developed to restore the activity of mutated TP53 protein. Oxidative stress related 
genes heme oxygenase-1 (HMOX1, also termed HO-1), SLC7A11 and RIT1 were 
significantly upregulated. Also, Nrf2 that induces the expression of HO-1 was 
upregulated and depletion of Nrf2 mRNA resulted in increased cytotoxicity of 
APR-246. Moreover, blocking Nrf2 from translocating into the nucleus by using 
PI3K and mTOR inhibitors led to enhanced cell killing. This suggests that a 
combination of APR-246 with PI3K and mTOR inhibitors improves sensitivity 
to APR-246 by interfering with the cellular response to ROS activation to achieve 
better anti-leukemic effects of APR-246.
In Study II, we aimed to define the potential of using stroma cells in diagnostic 
AML samples as a source of germline DNA. To obtain germline DNA, together 
with DNA from leukemic cells, it is essential to reliably define somatic mutations 
in AML cells. Consequently, we cultivated and expanded bone marrow stroma 
cells from vitally frozen mononuclear cells from AML patients with monosomy 7 
as well as defined somatic mutations. In vitro expanded bone marrow stroma cells 
were stable after 6 weeks of culture and were able to differentiate into adipocytes 
or osteocytes. We could also show that cultivated stroma cells do not harbour the 
somatic mutations found in the malignant cells. Thus, we could conclude that 
bone marrow stroma cells from diagnostic bone marrow samples could be used 
as a source of germline DNA in AML patients. 
In Study III, we studied the binding occupancy of the chromatin organizer CTCF 
in AML patient cells and compared it to binding in normal CD34+ cells. We found 
that AML cells display an aberrant increase of CTCF binding. Motif analysis 
revealed that gained CTCF sites are enriched for transcription factors such as PU.1, 
RUNX1 and CEBPA, which is found to be important for normal myeloid devel-
opment. TET2 mutated AML patients exhibit a greater gain of CTCF occupancy 
that is mainly annotated to promoters. Generally, gained CTCF sites were found 
to be hypomethylated and associated with genes that were upregulated in AML. 
Knockdown of CTCF in K562 cells resulted in loss of CTCF and decreased gene 
expression of targeted genes as well as loss of RUNX1 binding at common CTCF 
and RUNX1 binding sites. Knockdown of CTCF also resulted in increased dif-
ferentiation of K562 cells. In vitro exposure of AML patient cells with azacytidine 
resulted in major changes in CTCF occupancy where most gained sites restored the 
binding pattern found in normal CD34+ cells. In conclusion, our results suggest 
that an aberrant CTCF occupancy in AML can have a role in driving leukemogenic 
gene expression patterns in AML.          
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11 INTRODUCTION
1.1 Haematopoiesis
Haematopoiesis is a process that occurs in the bone marrow (BM) where terminally 
mature blood cells arise from pluripotent haematopoietic stem cells (HSCs) (Bao, 
Cheng et al. 2019). A distinctive characteristic of HSCs is self-renewal as well 
as multi-lineage differentiation (Weissman 2000). Common progenitors mediate 
this multistep differentiation process where HSCs divide into common lymphoid 
progenitors (CLPs) and common myeloid progenitors (CMPs). Adaptive immune 
T-, B- and NK cells and dendritic cells differentiate from CLPs while CMPs give 
rise to erythrocytes, megakaryocytes and myeloblasts which differentiate into 
innate immune cells (Fig. 1A). Cell fate is determined by a sequence of growth 
factor signals that activates the expression of lineage specific genes. On the other 
hand, transcription factors such as GATA1 and PU.1 are critical for early erythroid 
and myeloid differentiation, respectively (Arinobu, Mizuno et al. 2007, Suzuki, 
Shimizu et al. 2011). Ikaros is important for early lymphoid commitment of CLPs 
(Georgopoulos, Bigby et al. 1994) while EBF, E2A and Pax5 are essential for B-cell 
development (Nutt and Kee 2007) and GATA3 is required for early differentiation 
of T-cells (Ting, Olson et al. 1996). 
1.1.1 Bone marrow microenvironment
The genesis of multi-lineage blood cells takes place in the bone marrow. This 
is a heterogeneous and complex microenvironment that consists of various cell 
populations, primarily with the role to support and regulate haematopoiesis. Non-
haematopoietic bone marrow stroma (BMS) cells together with HSCs forms a so 
called niche which govern the fate of HSCs (Pinho and Frenette 2019). However, 
BMS consist of different cell types such as mesenchymal stem cells, osteolineage 
cells, adipolineage cells, endothelial cells and neurons which provide a sophisticated 
framework of regulatory mechanisms that drive haematopoiesis and maintains the 
balance between self-renewal and differentiation of HSCs (Kfoury and Scadden 
2015, Tikhonova, Dolgalev et al. 2019). This happens directly though cell-bound 
molecules or indirectly by secreted molecules. For instance, the two soluble fac-
tors CXC-chemokine ligand 12 (CXCL12) (Sugiyama, Kohara et al. 2006), stem 
cell factor (SCF) (Asada, Kunisaki et al. 2017) and cell-bound vascular cell adhe-
sion molecule 1 (VCAM-1), also known as cluster of differentiation 106 (CD106) 
(Dutta, Hoyer et al. 2015), are required for maintenance of HSC. Other factors 
like notch ligands and fibroblast growth factor 1 (FGF1) promote HSC prolifera-
tion (Calvi, Adams et al. 2003, Zhao, Perry et al. 2014). Overall, it is a complex 
process in which multiple factors are required to maintain normal haematopoie-
sis and haemostasis of HSC populations. Deregulation of this cross-talk between 
2HSCs and BMS cells can drive neoplasia. For instance, deficiency of retinoic acid 
UHFHSWRUȖ5$5ȖFDQOHDGWRGHYHORSPHQWRIDP\HORSUROLIHUDWLYHV\QGURPH
(Walkley, Olsen et al. 2007). Additionally, knockout of RNA-processing enzyme 
Dicer 1 gene in mesenchymal-derived stromal cells leads to the development of 
myelodysplastic syndrome (MDS) which can progress to acute myeloid leukaemia 
(AML) (Raaijmakers, Mukherjee et al. 2010). This shows that deregulated signals 
from the microenvironment can cause malignant transformation. 
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A. B.
)LJXUH+DHPDWRSRLHVLVDQG/6&VIRUPDWLRQ A) Normal haematopoiesis shows dif-
ferent stages of differentiation from HSC to mature blood cells. B) Development of AML 
and accumulation of LSCs in bone marrow.
31.2 Acute myeloid leukaemia (AML)
Acute myeloid leukaemia (AML) is a type of blood cancer in which myeloblasts 
fail to differentiate into mature functional cells. This results in accumulation of 
aberrant myeloid blasts in the bone marrow and deficiencies in innate immune 
cells, red blood cells and platelets. Leukemic stem cells (LSC) acquire early 
mutations that retain the ability of self-renewal and this might occur in HSCs or 
later during any step of differentiation (Fig. 1B). AML is a heterogeneous disease 
and there may be multiple LSC clones found within the same patient (Horton 
and Huntly 2012). AML is usually classified by a morphological increase in BM 
blasts under microscope, and can be further characterized by cell surface markers 
analysed by flow cytometry and genetic changes by chromosomal karyotyping 
and mutational screening.
1.2.1 AML classification
AML is a heterogeneous disease. The World Health Organization (WHO) classi-
fication of AML was introduced in 2001, is based on morphology, genetic analy-
sis by cytogenetics, and mutation screening as well as information on previous 
exposure to chemotherapy and radiation or previous MDS. This system classifies 
AML into four main categories; AML with recurrent genetic abnormalities, myel-
odysplasia-related AML, therapy-related AML and AML not otherwise specified. 
Recent advances in next-generation sequencing (NGS) technologies have made 
it possible to further subtype AML into sub-categories based on a more thorough 
genetic characterization. The last update of the WHO AML classification was 
published in 2016 (Arber, Orazi et al. 2016) (Table 1). Novelties in the last update 
include the establishment of two previously provisional entities to become new 
permanent entities: AML with NPM1 mutation and AML with biallelic mutation 
of CEBPA. AML with mutated RUNX1 is a new provisional entity. Although the 
primary diagnosis of AML is based on a bone marrow blast count above 20%, 
patients with translocations t(8:21), inv(16) or t(15:17) are classified as AML also 
with  lower blast counts. 
4Table 1. WHO update on AML classifications
Acute myeloid leukaemia (AML) and related neoplasms
AML with recurrent genetic abnormalities Acute myelomonocytic leukemia
AML with t(8;21)
(q22;q22.1);RUNX1-RUNX1T1
Acute monoblastic/monocytic 
leukemia
AML with inv(16)(p13.1q22) or  t(16;16)
(p13.1;q22);CBFB-MYH11 Pure erythroid leukemia
APL with PML-RARA Acute megakaryoblastic leukemia
AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A Acute basophilic leukemia
AML with t(6;9)(p23;q34.1);DEK-NUP214 Acute panmyelosis with myelofibrosis
AML with inv(3)(q21.3q26.2) or t(3;3)
(q21.3;q26.2); GATA2, MECOM Myeloid sarcoma
AML (megakaryoblastic) with t(1;22)
(p13.3;q13.3);RBM15-MKL1
Myeloid proliferations related to Down 
syndrome
Provisional entity: AML with BCR-ABL1 Transient abnormal myelopoiesis (TAM)
AML with mutated NPM1 Myeloid leukemia associated with Down syndrome
AML with biallelic mutations of CEBPA Blastic plasmacytoid dendritic cell neoplasm
Provisional entity: AML with mutated RUNX1 Acute leukemias of ambiguous lineage
AML with myelodysplasia-related changes Acute undifferentiated leukemia
Therapy-related myeloid neoplasms
Mixed phenotype acute leu-
kemia (MPAL) with t(9;22)
(q34.1;q11.2); BCR-ABL1
AML, NOS MPAL with t(v;11q23.3); KMT2A rearranged
AML with minimal differentiation MPAL, B/myeloid, NOS
AML without maturation MPAL, T/myeloid, NOS
AML with maturation
Adapted from (Arber, Orazi et al. 2016)
51.2.2 AML prognostic factors
European LeukemiaNet (ELN) recommendations are based on chromosomal and 
molecular aberrations as main measures to predict prognosis and treatment out-
come of AML (Dohner, Estey et al. 2017). Overall, age and pre-existing health 
issues have an adverse effect on treatment outcome and are often related to early 
death of AML patients (De Kouchkovsky and Abdul-Hay 2016). Standard risk 
stratification is based on cytogenetics and molecular abnormalities that classify 
AML patients into three risk groups with favourable, intermediate and adverse 
outcome, respectively. Although chromosomal abnormalities constitute the basis 
for the primary risk groups, commonly mutated genes such as NPM1, FLT3-ITD, 
CEBPA, RUNX1, TP53 and ASXL1 are part of the revised 2017 ELN classification 
(Table 2) (Dohner, Estey et al. 2017). Interestingly, most of these mutations are 
associated with normal karyotype which helps to give a more detailed classifica-
tion of cytogenetically normal AML (CN-AML) patients. Still, the prognostic 
impact of genetic markers is dependent on a co-existence of other genetic lesions 
in context-dependent manner. Further understanding of the role of co-occurring 
mutations is required in order to achieve better prognostication. 
6Table 2. 2017 ELN risk stratification by genetics
Favorable t(8;21)(q22;q22.1); RUNX1-RUNX1T1
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow†
Biallelic mutated CEBPA
Intermediate Mutated NPM1 and FLT3-ITDhigh†
Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow† (without
adverse-risk genetic lesions)
t(9;11)(p21.3;q23.3); MLLT3-KMT2A‡
Cytogenetic abnormalities not classified as favorable or adverse
Adverse t(6;9)(p23;q34.1); DEK-NUP214
t(v;11q23.3); KMT2A rearranged
t(9;22)(q34.1;q11.2); BCR-ABL1
inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1)
25 or del(5q); 27; 217/abn(17p)
Complex karyotype,§ monosomal karyotype||
Wild-type NPM1 and FLT3-ITDhigh†
Mutated RUNX1¶
Mutated ASXL1¶
Mutated TP53#
Frequencies, response rates, and outcome measures should be reported by risk category, 
and, if sufficient numbers are available, by specific genetic lesions indicated.
*Prognostic impact of a marker is treatment-dependent and may change with new therapies.
†Low, low allelic ratio (,0.5); high, high allelic ratio ($0.5); semiquantitative assessment of 
FLT3-ITD allelic ratio (using DNA fragment analysis) is determined as ratio of the area under 
the curve “FLT3-ITD” divided by area under the curve “FLT3- wild type”; recent studies indi-
cate that AML with NPM1 mutation and FLT3-ITD low allelic ratio may also have a more 
favorable prognosis and patients should not routinely be assigned to allogeneic HCT.
‡The presence of t(9;11)(p21.3;q23.3) takes precedence over rare, concurrent adverse-risk 
gene mutations.
§Three or more unrelated chromosome abnormalities in the absence of 1 of the WHO-
designated recurring translocations or inversions, that is, t(8;21), inv(16) or t(16;16), t(9;11), 
t(v;11)(v;q23.3), t(6;9), inv(3) or t(3;3); AML with BCR-ABL1.
||Defined by the presence of 1 single monosomy (excluding loss of X or Y) in association 
with at least 1 additional monosomy or structural chromosome abnormality (excluding core-
binding factor AML).
¶These markers should not be used as an adverse prognostic marker if they co-occur with 
favorable-risk AML subtypes.
#TP53 mutations are significantly associated with AML with complex and monosomal 
karyotype
Adapted from (Dohner, Estey et al. 2017) 
  
71.2.3 Genetics of AML
NGS techniques have significantly increased our knowledge about the genetic 
landscape of AML. In addition to the WHO classification, there are now additional 
suggestions on how to sub-classify AML based on the occurrence of different muta-
tions. In 2013, the first thorough genetic characterization of AML using NGS on 
a large scale in AML was published. This study suggests gene mutations in AML 
to be divided into nine groups, based on the normal function of the mutated gene 
(Fig. 2) (Ley 2013). 
FMS-like tyrosine kinase 3 (FLT3) receptor is expressed in hematopoietic pro-
genitor cells. Mutations in FLT3 intracellular tyrosine-kinase domain (FLT3-TKD) 
leads to constitutive proliferation activation signal through RAS-RAF, JAK-STAT 
or PI3K-AKT pathways (Fig. 2). Another mutation affecting the FLT3 gene is the 
FLT3-internal tandem duplication (FLT3-ITD) in exon 14 and 15, which occurs 
frequently in AML. FLT3-ITD results from duplications and insertion in the jux-
tamembrane domain of FLT3 receptor. The insertion varies between 3 bp to up 
to 400 bp; this causes an auto-phosphorylation of FLT3 receptor and a constant 
activation of the tyrosine kinase. AML patients with FLT3-ITD mutation usually 
have poor prognosis (Stirewalt and Radich 2003). 
5XQWUHODWHGWUDQVFULSWLRQIDFWRU581; is a transcription factor whose 
function has been implicated during early haematopoiesis (de Bruijn and Dzierzak 
2017). Around 6-18% of de novo AML patients carry a mutation in the RUNX1 
gene. Most commonly, this consists of the chromosomal rearrangement t(8;21) 
which results in a RUNX1-RUNX1T1 fusion. Double knockout of RUNX1 gene in 
adult HSCs affects the transactivation domain of RUNX1 and causes an increase in 
its DNA binding affinity, which leads to aberrant gene expression of downstream 
genes and results in multi-lineage differentiation blockage (Fig. 2). Further, bial-
lelic missense and nonsense point mutations in RUNX1 are reported to be associ-
ated with adverse prognosis in patients with CN-AML (Mangan and Speck 2011, 
Greif, Konstandin et al. 2012). 
The most common mutation in AML affects QXFOHRSKRVPLQNPM1). The 
NPM1 protein has been implicated in critical cell functions through interacting 
with multiple proteins and shuttling between the cytoplasm and nucleus. NPM1 
has been shown to be involved in stabilization of the Arf protein and ribosome 
biogenesis and export (Grisendi, Mecucci et al. 2006). An insertion mutation in 
the last exon of NPM1 causes loss of the nuclear localization signal and aberrant 
cytoplasmic cellular location (Fig. 2) (Falini, Mecucci et al. 2005, Falini, Bolli et 
al. 2006). This type of mutation is referred to as NPM1c. However, the molecular 
mechanism of how NPM1 mutations induces leukaemia is still not clear. Eviction 
of NPM1 from the nucleus along with their partner proteins potentially results in 
8disturbance of biological processes. A proposed mechanism of action of NPM1c 
in promoting leukemogenesis is by indirectly activating the onco-protein c-MYC 
through entrapping its suppressor Arf in the cytoplasm (Falini, Gionfriddo et al. 
2011). Other mutations in genes like DNMT3A and FLT3-ITD are often associ-
ated with NPM1 mutations in CN-AML (Papaemmanuil, Gerstung et al. 2016). 
While NPM1 mutations are associated with a good prognosis, when they co-occur 
with FLT-ITD, the prognosis worsens (Dohner, Schlenk et al. 2005, Schnittger, 
Bacher et al. 2011).
'1$PHWK\OWUDQVIHUDVHDOSKD'107$enzyme catalyses de novo DNA 
methylation. The DNMT3A gene is mutated in around 20-22% of all AML patients, 
preferentially in CN-AML (Ley, Ding et al. 2010, Gaidzik, Schlenk et al. 2013). 
Various types of mutations have been reported for DNMT3A, but heterozygous 
point mutations at arginine position 882 (R882) accounts for 58% of all DNMT3A 
mutations in AML patients. Functional studies on DNMT3AR882 mutation have 
revealed that the mutant enzyme has less DNA-binding affinity compared to the 
wild type. This results in reduced enzymatic activity, which in turn leads to DNA 
hypomethylation (Holz-Schietinger, Matje et al. 2012, Russler-Germain, Spencer et 
al. 2014). The prognosis of DNMT3A mutations is context-dependent and affected 
by other recurrent mutations such as NPM1 and FLT-ITD (Papaemmanuil, Gerstung 
et al. 2016). Moreover, DNMT3AR882H mutations have been found to cause global 
DNA hypomethylation in CN-AML patients (Qu, Lennartsson et al. 2014).     
Mutations in spliceosome related genes are recurrent in AML and mainly affect 
VSOLFLQJIDFWRUEVXEXQLWSF3B1), U2AF1, SRSF2 and ZRSR2. Mutations in 
these genes result in an impaired spliceosome machinery (Fig. 2) (Lindsley, Mar 
et al. 2015). Spliceosome mutations are more common in refractory anaemia with 
ring sideroblasts (RARS) and MDS compared to de novo AML and are seen more 
commonly in AML secondary to MDS. SF3B1 is the most investigated of the 
mutated spliceosome genes and a missense mutation that affects the core domain 
of SF3B1 protein causes aberrant RNA splicing. Targets of SF3B1 include genes 
such as EZH, RUNX and ASLX1 (Dolatshad, Pellagatti et al. 2015). 
9)LJXUH. Most recurrent mutated genes in AML based on their function. Reproduced with 
permission from (Dohner, Weisdorf et al. 2015), Copyright Massachusetts Medical Society
TP53 is a tumour suppressor gene that functions as a transcription factor that 
becomes activated in response to DNA damage. While TP53 mutations are found 
in 5-10% of AML patients, it is commonly associated with complex karyotype 
and an adverse prognosis. Mutations in TP53 leads to impairment of its activity 
and often, as a consequence, overexpression of its negative regulators mouse dou-
ble minute 2 homology (MDM2) and tensin homologue (PTEN) proteins (Fig. 2) 
(Kojima, Konopleva et al. 2005). 
The cohesin complex along with CTCF maintains chromatin looping and inter-
actions that regulate and facilitate gene regulation as well as chromosome con-
densation during cell divisions. Mutations in AML can affect cohesin complex 
subunits, mainly of two types, either truncating mutations in STAG2 and RAD21 
or missense mutations in SMC3 and SMC12A (Welch, Ley et al. 2012) (Fig. 2). 
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The exact mechanism by which different mutations impact the cohesin complex is 
to be further investigated. However, some mutations have been suggested to have 
dominant negative effect, while others induce transcript degradation. Interestingly, 
mutations in cohesin genes are mutually exclusive with DNMT3A, FLT3, NPM1 
and PTPN11 mutations. While cohesin mutations cause chromosomal instability 
and aneuploidy it is often found in CN-AML (Ley 2013).
Ten-eleven translocation (TET) methylcytosine dioxygenase (TET2) plays 
a key role in DNA demethylation through catalysing the conversion of methyl-
cytosine to 5-hydroxymethylcytosine (Ito, D’Alessio et al. 2010). Mutations in 
TET2 are loss of function mutations that cause global DNA hypermethylation 
(Figueroa, Abdel-Wahab et al. 2010). TET2 mutations are present in 23-27% of 
AML patient and commonly found in malignancies like MDS and myeloprolifera-
tive neoplasms (NPM) (Tefferi, Lim et al. 2009, Papaemmanuil, Gerstung et al. 
2016). Detection of TET2 mutations in early myeloid and lymphoid progenitors 
as well as in normal CD34+ cells, imply its role in clonal haematopoiesis (Smith, 
Mohamedali et al. 2010). In AML, TET2 mutations often occur together with 
NPM1, DNMT3A and FLT3 mutations (Papaemmanuil, Gerstung et al. 2016). It 
is still elusive how these mutations contribute to leukemogenesis. As mentioned, 
TET2 mutations are associated to hypermethylation and one affected locus is the 
GATA2 promoter causing gene downregulation leading to block in differentiation 
and leukaemia development (Shih, Jiang et al. 2015). The prognostic impact of 
the TET2 mutations has been debated and is still unclear. A recent meta-analysis 
looked at 16 studies and found an adverse effect of TET2 mutations on prognosis 
in general (Wang, Gao et al. 2019).   
,VRFLWUDWHGHK\GURJHQDVHDQGIDH1/2) are frequently mutated genes in 
AML. Whereas mutations in IDH1 are frequently affecting the arginine residue 
132 (IDH1R132), arginine 140 and 172 are frequently mutated in IDH2 (IDH2R140 
and IDH2R172 respectively). These are gain of function mutations that affect the 
catalytic domain of the IDH enzyme and consequently cause excessive conver-
VLRQRIDOSKDNHWRJOXWDUDWHĮ.*LQWRWKHRQFRPHWDEROLWHK\GUR[\JOXWDUDWH
(2-HG) (Ward, Patel et al. 2010). IDH2R140 is more common than IDHR172 despite 
that IDH1 and IDH2 mutations being mutually exclusive as with TET2 mutations 
(Gaidzik, Paschka et al. 2012). Furthermore, NPM1 mutations have been found 
to be mutually exclusive with IDH2R140 but not IDH2R172. The accumulation of the 
oncometabolite 2-HG in IDH1/2 mutated AML has been shown to lead to DNA 
hypermethylation (Fig. 2) (Figueroa, Abdel-Wahab et al. 2010, Stein, DiNardo 
et al. 2019). 
Mutations in chromatin remodelling genes like the histone modifiers additional 
sex comb-like (ASXL1) and HQKDQFHURI]HVWHKRPRORJEZH2) leads to loss 
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of histone methylation of H2AK119 and H3K27, respectively, which results in 
more open chromatin and decreased histone occupancy (Fig. 2) (Simon and Lange 
2008, Abdel-Wahab, Adli et al. 2012). ASXL1 is a putative member of polycomb 
group (PcG) and is mutated in 5-10% of AML patients, although more frequent 
(16%) in older patients (> 60 years) (Metzeler, Becker et al. 2011). While EZH2 
is a member PcG Repressive Complex 2 (PRC2), both ASXL1 and EZH2 interact 
to remove the repressive histone mark H3K27me3 (Gelsi-Boyer, Brecqueville et 
al. 2012).  
&&$$7(QKDQFHU%LQGLQJ3URWHLQĮ &(%3$ is an important transcription fac-
tor that is involved in granulocyte differentiation (Ma, Hong et al. 2014). Loss of 
function mutations in CEBPA have been reported in 15-19% of CN-AML patients 
(Longo, Döhner et al. 2015). In particular, biallelic mutations are common in 
CEBPA, where one allele could harbour a frame shift mutation which results in a 
truncated protein at its N-terminal, while the other allele has an insertion/deletion 
at the bZIP domain. Moreover, biallelic mutations in CEBPA predict a favourable 
prognosis and a higher complete remission rate (Fasan, Haferlach et al. 2014).       
More recently, Papaemmanuil et al., have conducted a study with 1540 intensively 
treated AML patients characterizing driver mutations, cytogenetics and the clinical 
data.  They proposed an additional genomic classification of AML, also based on 
its significance for clinical outcome. Three main genomic categories are proposed 
to be added to “AML with recurrent genetic abnormalities” within the WHO clas-
sification; namely 1) AML with mutations in chromatin-spliceosome genes, 2) 
AML with TP53 aneuploidy, and 3) AML with IDHR172 mutations. In total eleven 
subgroups are suggested and they are summarized in Table 3 (Papaemmanuil, 
Gerstung et al. 2016).
Mutations within the chromatin-spliceosome group includes AML types with aber-
rant RNA splicing (SRSF2, SF3B1, U2AF1 and ZRSR2), chromatin organization 
(ASXL1, STAG2, BCOR, MLLPTD, EZH2 and PHF6), or transcription (RUNX1). 
In their cohort, this group accounted for 18% of the patients. Furthermore, in 
the Papaemmanuil study, 13% of the AML patients had TP53 aneuploidy which 
defined a separate group (Papaemmanuil, Gerstung et al. 2016).  Interestingly, 
~16 AML patients had an IDHR172 mutation, which represents 1% of the cohort. 
While IDHR172 mutation has a role in gene expression and DNA methylation, it 
was found to occur less frequently with NPM1 mutations compared to IDHR140 
mutations which affects metabolic activity.
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Table 3. Suggested genomic classification of AML by Papaemmanuil et al. 2016.
Genomic Subgroup
Frequency in the Study 
Cohort (N = 1540) 
no. of patients (%)
Most Frequently Mutated 
Genes* 
gene (%)
AML with NPM1 mutation 418 (27) NPM1 (100), DNMT3A (54), 
FLT3ITD (39), NRAS (19),TET2 
(16), PTPN11 (15)
AML with mutated chromatin, 
RNA-splicing genes, or both†
275 (18) RUNX1 (39), MLLPTD 
(25), SRSF2 (22), DNMT3A 
(20),ASXL1 (17), STAG2 
(16), NRAS (16), TET2 (15), 
FLT3ITD (15)
AML with TP53 mutations, chro-
mosomal aneuploidy, or both‡
199 (13) Complex karyotype (68), 
íT(47), íT(44), TP53 
(44), íS(31), íS
(17), +8/8q (16)
AML with inv(16)(p13.1q22) 
or t(16;16)(p13.1;q22); 
CBFB–MYH11
81 (5) inv(16) (100), NRAS (53), 
+8/8q (16), +22 (16), KIT (15), 
FLT3TKD (15)
AML with biallelic CEBPA 
mutations
66 (4) CEBPAbiallelic (100), NRAS (30), 
WT1 (21), GATA2 (20)
AML with t(15;17)(q22;q12); 
PML–RARA
60 (4) W(100), FLT3ITD (35), 
WT1 (17)
AML with t(8;21)(q22;q22); 
RUNX1–RUNX1T1
60 (4) t(8;21) (100), KIT í<
íT
AML with MLL fusion genes; 
t(x;11)(x;q23)§
44 (3) t(x;11q23) (100), NRAS (23)
AML with inv(3)(q21q26.2) 
or t(3;3)(q21;q26.2); GATA2, 
MECOM(EVI1)
20 (1) inv(3) íKRAS (30), 
NRAS (30), PTPN11 (30), ETV6 
(15), PHF6 (15), SF3B1 (15)
AML with IDH2R172 mutations and 
no other class-defining lesions
18 (1) IDH2R172 (100), DNMT3A 
(67), +8/8q (17)
AML with t(6;9)(p23;q34); 
DEK–NUP214
15 (1) t(6;9) (100), FLT3ITD (80), 
KRAS (20)
AML with driver mutations but no 
detected class-defining lesions
166 (11) FLT3ITD (39), DNMT3A (16)
AML with no detected driver 
mutations
62 (4)
$0/PHHWLQJFULWHULDIRU
genomic subgroups
56 (4)
* Genes with a frequency of 15% or higher are shown in descending order of frequency. Key 
contributing genes in each class are shown in boldface type.
† Classification in this subgroup requires one or more driver mutations in RUNX1, ASXL1, 
BCOR, STAG2, EZH2, SRSF2, SF3B1, U2AF1, ZRSR2, or MLLPTD. In the presence of 
other class-defining lesions — namely, inv(16), t(15;17), t(8;21), t(6;9), MLL fusion genes, 
or complex karyotype or driver mutations in TP53, NPM1, or CEBPA biallelic — two or more 
chromatin–spliceosome mutations are required.
‡ Classification in this subgroup requires TP53 mutation, complex karyotype, or in the 
DEVHQFHRIRWKHUFODVVGHILQLQJOHVLRQVRQHRUPRUHRIWKHIROORZLQJíTíTíT
íTíSííSíTíTTRU
§ Multiple fusion partners for MLL were found, with the clinical implications depending on the 
specific fusion partner.
Reproduced with permission from (Papaemmanuil, Gerstung et al. 2016), Copyright 
Massachusetts Medical Society.
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1.2.4 Clonality and clonal evolution in AML
Clonal heterogeneity is common in AML where sub-clones originate from a found-
ing clone (Ley 2013). Furthermore, pre-leukemic HSCs have shown to acquire 
early initiation mutations such as DNMT3A followed by mutations such as NPM1, 
FLT-ITD (Shlush, Zandi et al. 2014). Analysis of HSC from healthy donors have 
shown that some harbour DNMT3AR882H mutation as a result of aging, but in order 
to develop AML, it requires a second genetic hit (Welch, Ley et al. 2012).
Figure 3. Graphical representation of the sequence of mutational events in HSCs. Adapted 
from (Welch, Ley et al. 2012)
Figure 3 shows a schematic representation of the sequence of mutational events 
from the time that the HSCs acquire an initiating mutation until AML develops 
and the generation of multiple sub-clones. The biological function of these muta-
tions will help understanding disease development in AML.
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1.2.5 Treatment of AML
During the last decades, there have been improvements in the treatment of AML 
with better survival following chemotherapy and hematopoietic stem cell trans-
plantation HCST.  
Induction therapy
The first line treatment in AML is named induction therapy and aims to eliminate 
leukemic blast cells to achieve a complete remission (CR). Classically, patients 
undergo daily cytarabine infusions for 7 days and anthracycline for 3 days, which 
known as the “7+3” treatment regimen. This is the preferred treatment for patients 
under the age of 70 and fit elderly patients (Dohner, Estey et al. 2017). CR is 
archived when BM blasts are <5%, platelets >100000/μl and neutrophil count 
>1000/μl (Cheson, Bennett et al. 2003). Younger patients have better CR rates (60-
75%) compared to older patients (38-60%) (Longo, Döhner et al. 2015). Patient 
fitness is the main criteria for deciding treatment strategy and not age alone. Older 
AML patients with complex karyotype and TP53 mutations may preferably be 
treated with the hypomethylating agents decitabine or azacitidine instead of inten-
sive induction therapy, since these patients are highly resistant to chemotherapy 
(Quintas-Cardama, Ravandi et al. 2012, Klepin 2014). 
Consolidation therapy
Consolidation therapy is a post-remission treatment to eliminate minimal residual 
disease (MDR) to prevent relapse. Usually it starts with chemotherapy and is fol-
lowed by hematopoietic stem cell transplantation (HSCT). MRD is most commonly 
analysed by flow-cytometry for aberrant immune-phenotypes but genetically based 
MRD is increasingly utilized using conventional or next-generation sequencing 
techniques (Kohlmann, Nadarajah et al. 2014, Bill, Grimm et al. 2018). Patients 
within the favourable ELN genetic risk category have been suggested to benefit 
from repeated courses of high doses of cytarabine. Moreover, some studies have 
suggested combination therapy post-remission for adverse- risk cytogenetics group 
but have not shown better outcome compared to only cytarabine (Burnett, Russell 
et al. 2013). Importantly, intermediate and adverse risk group AML patients who 
are eligible for transplantation and achieve CR, are usually subjected to allogeneic 
HSCT. (Popat, de Lima et al. 2012). 
New Therapies
Improving treatment outcome has always been a concern in AML and the devel-
opment of new potent and less toxic drugs, resulting in novel therapeutic oppor-
tunities for AML, are examined continuously in clinical trials. Several of the new 
emerging drugs target specific recurrent mutations in AML. For instance, the first 
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generation of FLT3 inhibitors (sorafenib, sunitinib and midostaurin) have been 
shown to have a role in FLT3 mutated AML but they also have off target effects 
as a result of their activity on other kinases (Weisberg, Roesel et al. 2010). More 
recently, second generation FLT3 inhibitors (crenolanib, gilteritinib and quizarti-
nib) have shown higher specificity, potency and less toxicity due to less off target 
activity. First and second generation FLT3 inhibitors are also categorized based on 
their mechanisms of action; Type I (midostaurin, lestaurtinib, sunitinib, gilteritinib 
and crenolanib) and Type II (ponatinib, sorafenib and quizartinib). While Type I 
competes with ATP molecules and binds to the ATP-binding site of active tyros-
ine kinase domain (TKD), Type II blocks the activation of TKD when interacting 
with its hydrophobic region (Ke, Singh et al. 2015). To date, midostaurin results 
in a better survival in AML patients with FLT3 mutation and been approved by 
FDA in combination with induction therapy. Meanwhile, gilteritinib is approved 
for relapsed or refractory AML patients with FLT3 mutation (Dohner, Estey et al. 
2017). Additionally, AML patients with FLT3 mutations that are unfit for intensive 
induction treatment have been suggested to benefit from a combination of FLT3 
inhibitors and hypomethylating agents (i.e. azacytidine and decitabine).   
Other new promising treatment approaches include IDH inhibitors such as 
enasidenib, which blocks mutated IDH2 enzyme from excessively producing 
the 2-HG onco-metabolite and thereby promotes differentiation (Yen, Travins et 
al. 2017). Enasidenib has shown surprisingly good CR rates as monotherapy in 
relapsed or refractory AML patients and received FDA approval for clinical use 
(Stein, DiNardo et al. 2017). Likewise, ivosidenib inhibits mutated IDH1 enzyme 
and has similar results as enasidenib. As for TET2 mutations, IDH mutation is 
associated with DNA hypermethylation and therefore, IDH inhibitors have been 
suggested to be combined with hypomethylating agents.
APR-246 is a small molecule that has been developed to specifically target mutated 
p53 protein by restoring the 3D structure of the mutated protein, and consequently 
to induce cell cycle arrest and apoptosis (Bykov and Wiman 2003). Since it has 
shown promising results in early clinical trials, APR-246 has now entered phase 
III clinical studies to prepare for registration in TP53 mutated malignancies 
(Deneberg, Cherif et al. 2016). Although it has been developed to target mutant 
TP53, p53-independent effects have also been reported including the induction of 
oxidative and ER stress (Ali, Mohammad et al. 2016). In vitro experiments have 
shown that a combination APR-246 with other drugs improves cytotoxicity and 
can have synergistic effects in cancer cells. For instance, good combination effects 
have been shown in combination with cisplatin in ovarian cancer cells (Kobayashi, 
Abedini et al. 2013). Similarly, combination with wortmannin (PI3K inhibitor) 
or rapamycin (mTOR inhibitor) shows an increased cytotoxicity in primary AML 
cells (Ali, Mohammad et al. 2016). 
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1.3 Epigenetics of AML
AML differs from many other cancer types as it contains fewer genetic lesions 
compared to most other malignant diseases. On average, each patient harbours 13 
potentially pathogenetic genetic mutations, of which five can be considered to be 
recurrent mutations (Ley 2013). Interestingly, many of these genetic mutations 
occur in pre-leukemic HSCs and commonly affect epigenetically regulating genes 
such as DNMT3A, TET2, IDH1/2 and EZH2 (Walter, Shen et al. 2012, Shlush, 
Zandi et al. 2014). Indeed, aberrant DNA methylation is significant in AML and 
studies have shown that different subtypes of AML exhibit distinguished DNA 
methylation profiles dependent on the type of genetic mutation, which could also 
be in genes such as NPM1 and CEBPA (Figueroa, Lugthart et al. 2010, Ley 2013).
1.3.1 Aberrant DNA methylation in AML
DNA methyltransferases (DNMTs) are a family of enzymes that have the ability to 
add methyl groups to cytosine residues. This process maintains the DNA methyla-
tion profile during replication by DNMT1 or catalyses de novo DNA methylation 
by DNMT3A and DNMT3B (Goll and Bestor 2005). In contrast, TET enzymes 
mediate a step in the removal of DNA methylation. In normal hematopoietic cells, 
WKH,'+HQ]\PHFDWDO\VHVGHFDUER[\ODWLRQRILVRFLWUDWHWRĮ.*PHDQZKLOH
7(7FDWDO\VHVK\GUR[\ODWLRQRI0HWK\OF\WRVLQHP&QXFOHRWLGHLQDĮ.*
dependant manner, resulting in 5-hydroxymethylcytosine (5hmC) which leads to 
DNA demethylation (Yang, Ye et al. 2012).
AML cells with DNMT3AR882H mutation display a global hypomethylated pattern 
compared to patients with wild-type DNMT3A (Qu, Lennartsson et al. 2014). This 
can result in activation of enhancers mediated by histone modifications, which can 
lead to aberrant expression of the HOXA cluster (Lu, Wang et al. 2016). R882H 
mutations exert a dominant negative effect on DNMT3A reducing its catalytic 
methyltransferases activity. Although DNMT3AR882H is able to form dimers, it fails 
to methylate neighbouring CpGs once it binds to the target site due to lack of the 
more effective tetramers and this causes a scattered methylation pattern (Ley, 
Ding et al. 2010). DNMT3AR882H mutations are found in pre-leukemic HSCs that 
undergo subsequent clonal evolution in a process leading to AML development. 
Unfortunately, there are currently no drugs targeting DNMT3A mutations, which 
potentially could be a way to prevent pre-leukemic lesions to develop to AML. On 
the other hand and as described above, mutations in TET and IDH genes impair 
DNA demethylation causing global hypermethylation (Figueroa, Abdel-Wahab et 
al.6LQFH7(7LVGHSHQGHQWRQĮ.*LWEHFRPHVLQKLELWHGE\+*ZKLFK
causes genome-wide hypermethylation (Figueroa, Abdel-Wahab et al. 2010). In 
a mouse model, overexpression of mutated IDHR132H resulted in a block in differ-
entiation within the myeloid lineage, however, AML was not developed solely 
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based on the introduction of an IDH R132H mutation which shows that other lesions 
also are needed for AML development (Sasaki, Knobbe et al. 2012). Furthermore, 
TET2 and IDH mutations are mutually exclusive and both these mutations result 
in a similar pattern of global DNA hypermethylation (Figueroa, Abdel-Wahab et 
al. 2010, Ley 2013). Functional studies have shown that TET2 mutations abrogate 
the enzymatic activity of wild-type TET2 function (Rickman, Soong et al. 2012). 
Rasmussen et al. have reported TET2 to be expressed in pre-leukemic HSCs in a 
murine model and they found that DNA hypermethylation targets active enhancer 
regions (Rasmussen, Jia et al. 2015). Moreover, TET2 mutations in combination 
with FLT3-ITD cause differentiation block, leading to accumulation of GMP cells 
(Shih, Jiang et al. 2015). In addition, TET2 mutations can alter gene expression 
through methylating the consensus binding site of chromatin remodelling protein 
CTCF (Marina, Sturgill et al. 2016).
1.3.2 Chromatin remodeling proteins and CTCF
There is an interplay between DNA methylation, chromatin interactions and chro-
mosomal architecture. As mentioned above, aberrant methylation can affect the 
binding of the architectural protein CTCF, causing a change in chromatin looping 
and gene expression. CTCF is a key player in chromatin organization working 
together with cohesin in order to shape the chromatin architecture through regulat-
ing chromatin looping and formation of topologically associating domains (TADs) 
(Wendt, Yoshida et al. 2008, Merkenschlager and Odom 2013). Interestingly, and as 
described above, genes building up the cohesin complex subunits STAG2, SMC3, 
SMC12A and RAD21 are recurrently mutated in AML (Welch, Ley et al. 2012). 
Furthermore, cohesin and CTCF co-localize in the nucleus and they work together 
to facilitate chromatin interactions (Feinberg and Tycko 2004, Merkenschlager and 
Odom 2013). Also, CTCF recruits cohesin to exert its insulator function by loop-
ing out enhancers (Merkenschlager and Odom 2013, Losada 2014). The formation 
of DNA loops begins with extruding DNA through the cohesin ring complex and 
once the cohesin ring encounters CTCF, the loop becomes stabilized and forms a 
TAD (Fudenberg, Imakaev et al. 2016). Knockout studies of cohesin and CTCF 
have caused loss of chromatin interactions and altered chromatin looping as well 
as change in gene expression patterns (Zuin, Dixon et al. 2014). 
DNA methylation has been suggested to shape the occupancy to TFs (Maurano, 
Wang et al. 2015). On the other hand, TFs can protect from DNA methylation. 
For example, SP1 binds to unmethylated CpGs and protects it from de novo DNA 
methylation (Brandeis, Frank et al. 1994). Also, CTCF maintains Igf2-H19 region 
unmethylated (Schoenherr, Levorse et al. 2003). Despite the anti-correlation 
between CTCF binding and DNA methylation, some CTCF binding sites are insen-
sitive for DNA methylation. This can be due to absence of CpGs in CTCF binding 
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motif (Maurano, Wang et al. 2015). Furthermore, some methylation insensitive TFs 
(for instance PU.1) bind to methylated DNA loci and induce DNA demethylation 
through recruiting TET enzymes (de la Rica, Rodriguez-Ubreva et al. 2013). This 
suggests how TFs could change chromatin structure through a dynamic alteration 
of DNA methylation. Interestingly, using CRISPR-dCas9 to modify sequence spe-
cific sites of DNA methylation, this can result in gains or losses of CTCF binding 
when combined with dCas9-TET2 or dCas9-DNMT3A respectively (Liu, Wu et 
al. 2016). Furthermore, knockout of TET1 and TET2 genes in mouse embryonic 
stem cells result in a change of CTCF occupancy and can lead to changes in gene 
express of neighbouring genes (Wiehle, Thorn et al. 2019). Hence, aberrant DNA 
methylation in AML can potentially influence the three dimensional structure of 
the chromatin through altering CTCF binding. Moreover, CTCF interacts with 
the NPM1 protein. Mutations affecting NPM1 localization (NPM1c) can cause 
delocalisation of CTCF, consequently leading to aberrant gene expression (Wang, 
Han et al. 2019). CTCF is critical for maintaining chromatin boundaries of HOXA 
gene clusters and disruption of CTCF binding sites at these boundaries results in 
HOXA9 upregulation in AML cells (Luo, Wang et al. 2018). Similar effects on 
HOXA9 has been reported following CTCF delocalisation in NPM1c mutated cells 
(Wang, Han et al. 2019). 
Histone modifications play a key role in chromatin remodelling and regulation 
of the chromatin status (Schubeler, MacAlpine et al. 2004). For example, mono-, 
di- and trimethylation of H3K79 by the histone methyltransferase DOT1L can 
lead to gene activation. High expression levels of DOT1L were found in AML 
with mixed-linkage leukaemia (MLL) (Liu, Deng et al. 2014). Overexpression 
of DOT1L causes H3K79 methylation in HOXA9 promoter leading to upregula-
tion of HOXA9, which has been shown to be critical for leukaemia development 
(Chen and Armstrong 2015).  
Conversely, CTCF maintains gene repression by looping out and insulating genes 
through stabilization of polycomb domain boundaries. Thus, depletion of CTCF 
causes destabilization of polycomb domains and results in aberrant gene expres-
sion (Zhang, Niu et al. 2011, Dowen, Fan et al. 2014). Gain of function mutations 
in EZH2 results in spread of H3K27me3 that leads to downregulation of tumour 
suppressor genes (Donaldson-Collier, Sungalee et al. 2019), which suggests this 
could be mediated by a gain of CTCF occupancy in order to stabilize repressive 
polycomb domain. Indeed, knockdown of CTCF in hepatocellular carcinoma 
causes loss of CTCF and EZH2 binding, decreased H3K27me3 marks and DNA 
hypomethylation at SOCS3 promoter. CTCF depletion led to SOCS3 upregulation 
which confirms the role of CTCF in gene silencing through recruitment of PcG 
subunits (Wei, Liu et al. 2020). In line with this, ASXL1 is important for normal 
haematopoiesis (Abdel-Wahab, Gao et al. 2013) through interaction with cohesin 
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and stabilization of RAD21 and SMC1A subunits, mainly in promoter regions. 
Moreover, loss of ASXL1 leads to genome wide decrease of cohesin occupancy and 
aberrant expression of genes that are critical for myeloid development (Li, Zhang 
et al. 2017). However, the direct impact of ASXL1 mutation on chromatin structure 
has not yet been studied. Recently, cohesin was found to disrupt polycomb chro-
matin domain interactions in a CTCF independent manner. Furthermore, depletion 
of cohesin in ESCs led to stabilization of polycomb chromatin domain interactions 
and repression of polycomb target genes (Rhodes, Feldmann et al. 2020).  
However, despite the key role of CTCF for gene expression, chromatin immu-
noprecipitation sequencing (ChIP-seq) data on CTCF occupancy in AML cells is 
still lacking. Such studies could reveal the impact of DNA methylation on CTCF 
binding and chromatin architecture in AML. Also, it could elucidate how differ-
ent mutations in AML in genes such as DNMT3A, TET2, IDH1, IDH2 and NPM1 
influence the 3D structure of the chromatin through changed CTCF binding in 
the nucleus.
20
2 AIM OF THE THESIS
With this thesis, we aim to increase the understanding of the genetic and epige-
netic basis of AML.
3DSHU,
To examine the effect of APR-246 on AML cells and the role of oxidative stress 
LQHQKDQFLQJGUXJUHVSRQVHWKURXJKLQKLELWLQJWKHSURWHFWLYHUHVSRQVHRI1UIဨ
HMOX1.
3DSHU,,
To find a reliable source of germline DNA in bio-banked AML samples for genetic 
studies.
3DSHU,,,
To explore aberrant CTCF patterns in AML cells and the impact of certain muta-
tions on CTCF occupancy.
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3 METHODOLOGICAL APPROACHES
Detailed and comprehensive descriptions of experimental methodologies used to 
generate the data in this thesis are described in papers I-III. Key experiments are 
discussed below.
3.1 Cell culture and transfection
Throughout the projects various cell types and methods have been used to grow 
cells in vitro. Classically, immortalized cell lines were cultivated in suitable 
medium while primary cells required more optimized conditions to grow in vitro, 
as described below.
3.1.1 Bone marrow stroma culture
During BM aspiration from AML patients, stroma cells are also collected in the 
sample. To isolate stroma cells from BM samples, we used the ability of stroma 
cells to adhere the to plastic surface of culture flasks. In order to maximize cell 
recovery for culture, we cultured total mononuclear cells in culture flasks in 
MyeloCult™ H5100 (STEMCELL Technologies) supplemented with 10% FBS 
for the first two weeks. Thereafter, unattached cells (i.e., leukemic cells, lympho-
cytes etc.) were washed away. Then, new fresh DMEM-GlutaMax medium with 
10% FBS was added to stroma cells for up to six weeks.
3.1.2 Primary AML cell culture
To assess the effect of different drugs on AML blast cells in vitro, cells were 
grown in duplicate in culture flasks. A modified protocol of long-term culture of 
AML cells without feeder cells was used (Griessinger, Anjos-Afonso et al. 2014). 
Total mononuclear cells from bone marrow aspirations were suspended in RPMI 
1640 medium with 10% FBS supplemented with IL3, IL6, SCF (R&D Systems), 
GM-SCF, G-CSF and Flt- 3/flk2 ligand (STEMCELL Technologies). Cells were 
seeded onto 6-well plates and incubated at 37ºC and 5% CO2.
3.1.3 RNA interference and transfection
RNA interference is a biological mechanism by which cells can control gene 
expression. Small interfering RNAs (siRNA) and mircoRNAs (miRNAs) are 
two of the main categories of non-coding RNA. siRNAs are derived from longer 
double-stranded RNAs that are produced by the cell. siRNAs are produced by an 
endonuclease protein called dicer, which cleaves along preRNA into short frag-
ments (20-30 nucleotides). Then, double-stranded siRNA binds to the argonaute 
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protein whose antisense strand gets selected and stays bound to argonaute. Other 
proteins bind to siRNA-argonaute to form RNA-induced silencing complex (RISC). 
Antisense siRNA guides RISC to target mRNA. Once aligned to a perfect sequence 
match, catalytic RISC protein cleaves mRNA molecules that then will be degraded 
(Dana, Chalbatani et al. 2017). Scientists have used this approach by introducing 
synthetic siRNAs to manipulate and silence gene expression. In study I, we used 
siRNA to target Nrf2 in KBM3 and HG3 cells. While in study III, siRNA were 
targeting CTCF in K562 cells. NEON electroporation system was used to transfect 
the cells, which in principle uses electric current to create temporary pores in cell 
membranes allowing molecules to diffuse into cells.
3.2 Mutation detection by targeted sequencing
Pyrosequencing is a sequencing-by-synthesis method in which DNA polymerase 
complements single stand DNA and incorporates appropriate nucleosides. As a 
result, pyrophosphate is produced which then is converted to ATP by ATP sulfu-
rylase. Finally, luciferase utilizes the ATP molecule to generate light signal as an 
indication of a successful addition of either an A, T, C or G base (Harrington, Lin 
et al. 2013).  In study II we used pyrosequencing to detect somatic mutations in 
BMS cells by designing specific primers targeting the mutations of interest.
3.3 Fluorescence-activated cell sorting
Fluorescence-activated cell sorting (FACS) is a technique used to analyse and 
separate cell populations based on cell surface antigens (Cluster of differentia-
tion (CD) markers). Cells are mixed with fluorophore-conjugated antibodies that 
recognize a specific CD marker, then passed through a beam of laser that excites 
the fluorophore that is bound to the antibody at a certain wave length where the 
emission is captured by a detector. A computer software analyses the signals to 
identify different cells types. 
Since AML samples usually have a heterogeneous set of leukemic blast popula-
tions carrying different surface markers, we used a negative sorting strategy to sort 
out non-leukemic cells. CD45, CD3, CD19 and Nkp45 were used to mark T-cells, 
B-cells and NK cells, respectively, while CD33 was used to mark myoblasts and 
Aqua to determine and sort cells based on viability. We defined leukemic blast cells 
as CD45-, CD3-, CD19-, Nkp45-, Aqua negative and either CD33+ or CD33-. To 
minimize the impact of sorting on cells, samples were stained and formaldehyde 
fixed upon sorting only for ChIP-seq experiment. We used this strategy for the 
isolation of leukemic blast cells in paper III (Fig. 4).
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Eukaryotic cells produce reactive oxygen species (ROS) as part of their normal 
metabolism. This results in the production of hydroxyl radical (OH) and hydrogen 
peroxide (H2O2) which contribute to intracellular oxidative stress. The develop-
ment of fluorescent probes has made it possible to detect intercellular ROS using 
flow cytometry (Cossarizza, Ferraresi et al. 2009). A non-fluorescent H2DCFH-DA 
molecule is used to detect ROS. It is highly sensitive to intracellular redox change 
and is a cell-membrane permeable dye. H2DCFH-DA enters the cell, and then, 
HVWHUDVHHQ]\PHVFOHDYHLWLQWRƍƍGLFKORURGLK\GURIOXRUHVFHLQ+2DCF) which 
then utilize H2O2 to oxidize H2DCF into the fluorescent molecule dichlorofluores-
cein (DCF). The signal emitted from DCF can be detected and quantified by flow 
cytometry or fluorescent microscopy. In study I, KBM3 cell cells were treated 
with different concentrations of APR-246 drug and cells were then stained with 
H2DCFH-DA for 20 minutes and immediately analysed by flow cytometry. H2O2 
was used as a positive control along with H2DCFH-DA.
3.4 Immunocytochemistry
Immunocytochemistry is a method to detect intracellular proteins using a specific 
antibody that is linked to a fluorescent dye, which can be detected by microscope 
(Burry 2011). Cells are fixed and permeabilized with paraformaldehyde in order to 
allow antibodies to enter the cells. In study I, a primary mouse IgG antibody was used 
to detect human Nrf2 protein, while a FITC-labelled anti-IgG secondary antibody was 
used to visualize the detection of Nrf2. The signal was detected by confocal microscope. 
3.5 Glutathione live detection
Thioltracker Violet is a thiol-reactive fluorescent dye used to detect intercellular 
reduced thiol (Mandavilli and Janes 2010). In study I, following the exposure of 
primary AML cells with APR-246, cells were stained with Thioltracher Violet dye 
and visualized under fluorescent microscope. 
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3.6 DNA methylation detection
The recent development of sequencing technologies and microarrays has made is 
possible to detect single nucleotide DNA methylation genome wide. In paper III, 
Infinium MethylationEPIC BeadChip was used.
3.6.1 Bisulfite conversion
Sequencing technologies are not able to directly detect 5mC and distinguish it from 
cytosine (C). However, chemical modification of C in a process called bisulfite 
conversion has made it possible to detect 5mC in whole genome (Hayatsu, Shiraishi 
et al. 2008). Treating genomic DNA with sodium bisulfite causes deamination of 
C into uracil (U), while 5mC remains protected from deamination by the methyl 
group. This allows detection methylation levels on single-nucleotide resolution by 
calculating the C/T ratio after PCR amplification. The main disadvantage of bisulfite 
conversion method is the fragmentation of genomic DNA caused by the harsh 
chemical treatment and also, its inability to distinguish between 5hmC and 5mC. 
3.6.2 Illumina methylation arrays
The Infinium MethylationEPIC BeadChip (IlluminaEpic array) is a probe-based 
array that consists of the original HumanMethylation450 BeadChip with an addi-
tional 400,000 CpGs that mainly cover enhancer and other non-CpG island regions 
(Pidsley, Zotenko et al. 2016). IlluminaEpic array employs both Infimum type I 
and type II probes (Bibikova, Lin et al. 2006). Following bisulfite conversion and 
genomic DNA amplification and purification, BS converted DNA is applied to 
the BeadChip to hybridize with the probe on the chip. For Infinium type I, two 
probes are dedicated for same loci to detect either methylated or unmethylated 
CpG. However, Infinium type II, uses a single probe per loci where the 3’ prime 
end hybridize directly upstream to the target CpG. Single nucleotide extension 
allows the incorporation of a fluorescently-labelled G or A to detect either meth-
ylated or unmethylated loci.
3.6.3 Whole genome bisulfite sequencing
Whole genome bisulfite sequencing (WGBS) or BS-Seq is the optimal method for 
genome-wild methylation profiling. The principle of WGBS is combining high-
throughput NGS and bisulfite converted DNA (Mill, Yazdanpanah et al. 2006). 
Sequenced reads are mapped to the reference genome using specialized alignment 
algorithms that identifies C to T transitions and marks it as unmethylated cytosine. 
This powerful method can detect methylation status at single nucleotide resolution 
genome-wide. However, since it is dependent on BS DNA, it is not possible to 
differentiate between 5mC and 5-hydroxymethylcytosine (5hmC).
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DNA strands are wrapped around histone proteins to form nucleosomes, which is 
referred to as euchromatin (Hewish and Burgoyne 1973, Hyde and Walker 1975). 
Furthermore, other transcription factors and structural protein are also interact-
ing with genomic DNA. To investigate these interactions between proteins and 
DNA, chromatin immunoprecipitation (ChIP) technique is used (Collas 2010). 
Molecules within the nucleus are in dynamic interaction so it is critical to fix the 
cells first where formaldehyde is used for the cross-linking of DNA to protein. 
To detect the specific loci of certain protein-DNA interactions, fixed chromatin 
must be fragmented using sonication. This is followed by immunoprecipitation by 
adding an antibody that recognizes the protein of interest to pull it down as DNA-
bound protein complexes. While heat is used to reverse the cross-linking, proteases 
digest bound proteins so that DNA can be purified for downstream analysis (Fig. 
5). Classically, PCR was used to amplify a genomic target loci where a protein of 
interest could possible bind. However, with the development of NGS, it is now 
possible to combine ChIP and sequencing (ChIP-seq) which makes it possibly to 
map proteins bound to DNA on a genome-wide level.
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3.8 RNA sequencing
RNA sequencing is a method for whole transcriptome profiling using NGS tech-
nology. Briefly, total RNA is purified and transcribed to cDNA. The cDNA is 
then used to prepare sequencing libraries. In this case single-end sequencing was 
performed producing reads with an average length of 50 bp. Following alignment 
to the reference genome, this generates information of gene expression.
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4 RESULTS AND DISCUSSION
4.1 Paper I
Mutations in the tumor suppressor TP53 has been associated with resistance to 
chemotherapy in many cancers (Wattel, Preudhomme et al. 1994, Breen, Heenan 
et al. 2007). More than half of AML patients with a complex cytogenetic profile 
harbour mutant TP53 (Rucker, Schlenk et al. 2012). APR-246 is a small molecule 
that has been developed to reactivate mutant TP53 protein (Bykov, Issaeva et al. 
2002). However, off-target effects have previously been reported for APR-246 
and such effects have also been found to induce apoptosis in primary AML cells 
regardless of TP53 status (Ali, Jonsson-Videsater et al. 2011). Our goal was to 
further investigate the effects of APR-246 in AML. Expression profiling of KMB3 
AML cell following exposure to APR-246 revealed that genes related to oxidative 
stress and heat shock were the most affected by APR-246 exposure. Among these 
genes were HMOX1, RIT1 and SLC7A11, that had protective effects against ROS. 
Expression of HMOX1 is inversely correlated with intercellular GSH and analysis of 
GSH in AML patient cells showed a dose-dependent reduction of intracellular GSH 
in response to APR-246 exposure. Furthermore, the combination of APR-246 with 
*6+LQKLELWRUEXWKLRQLQHဨ>65@ဨVXOIR[LPLQH%62UHVXOWHGLQDQH[WHQVLYHNLOOLQJ
RI.0%$0/FHOOV,QDGGLWLRQZHXVHGWKH526VFDYHQJHU1ဨDFHW\OF\VWHLQH
(NAC) to confirm that ROS induced by APR-246 exposure caused HMOX1 up-
regulation. NAC demolished the effect of APR-246 on HMOX1 while exhibiting 
minimal cytotoxicity. On the other hand, we found that upregulation of HMOX1 
was independent from TP53 mutational status in HCT116 colon cancer cell lines. 
Four different clones of HTC116 with either TP53wt/wt, TP53null/null, TP53R243w/wt or 
TP53R248W/null were treated with APR-246 and HMOX1 expression was found to be 
upregulated in all four clones. Moreover, nuclear factor erythroid 2-related factor 2 
(NRF2L) was activated upon exposure to APR-246. NRF2L is a transcription fac-
tor that binds to HMOX1 promoter and induces its expression (Dhakshinamoorthy 
and Jaiswal 2001). Immunostaining of APR-246 treated KMB3 cells for NRF2L 
protein showed translocation for the protein from the cytoplasm and to the nucleus. 
NRF2L also had increased expression at the transcriptional level as measured by 
qPCR. To confirm that NRF2L mediates HMOX1 activation following APR-246 
exposure, we knocked down NRF2L in KMB3 cells and then incubated them with 
APR-246. As anticipated, HMOX1 expression was suppressed. However, KMB3 
cells with NRF2L knockdown were more sensitive to the cytotoxic effect of APR-
246. To overcome the protective effect ROS, we combined the use of PI3K inhibi-
WRUVZRUWPDQQLQDQGWKHP725LQKLELWRUUDSDP\FLQZLWK$35ဨ$VDUHVXOW
we could detect an improved anti-leukemic effect of APR-246.
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4.2 Paper II
Advances in next generation sequencing (NGS) techniques have opened the doors 
for genome-wide characterization of genetic lesions in various cancers (Shao, Lin 
et al. 2016). In order to properly identify somatic genetic mutations in cancers, the 
use of reference germline DNA is crucial, and thus, it is important have access to 
a reliable source of germline DNA from non-malignant cells from same patient. 
There are studies using skin biopsies, buccal swabs and buccal washes from AML 
patients. However, these samples are often infiltrated by leukemic blast cells that 
makes the analysis more complicated (Ley, Mardis et al. 2008). In addition, they 
require separate invasive or non-invasive sampling which is not achieved retro-
spectively in deceased patients.  T-cells are often also used as a source of germline 
DNA, however, evolutionary early somatic mutations such as DNMT3A mutations 
can be found in T-cells as well as in the leukemic clone (Shlush, Zandi et al. 2014). 
In this study, we utilized bio-banked vitally frozen mononuclear cells from the 
diagnostic bone marrow sample as a source of germline DNA. Thus, we focus on 
non-hematopoietic cells in the diagnostic AML sample and hypothesized that bone 
marrow stroma (BMS) cells would be a reliable source. BMS cells were expanded 
in culture for up to six weeks to get enough genomic material and get rid of leuke-
mic cells. Six AML patients, of which five harboured monosomy 7, were selected 
for the study. The presence of monosomy 7 facilitated the monitoring of malignant 
cells in the BMS population using Fluorescence in-situ hybridization (FISH). After 
six weeks of culture, BMS cells from all patients showed disomy of chromosome 
seven. The morphological appearance of BMS cells was consistent with a fibro-
blast-like shape with large nuclei. In immunophenotypical analysis of cell surface 
markers in AML and BMS cells by flow cytometry, AML blasts were positive for 
CD45, CD117, CD34, CD38, HLA-DR and CD13. However, one AML sample 
was also positive for CD7 and CD19, defining a biphenotypic AML. In contrast, 
expanded BMS cells did not express CD45 or CD34 but were positive for CD90, 
CD105 and CD73, a phenotype similar to that of mesenchymal stem cells (MSCs). 
Furthermore, differentiation assay showed that BMS cells could differentiate into 
either adipocyte or osteoblasts but not chondroblasts. This indicates that BMS cells 
are still able to differentiate to osteogenic cells after a long time in culture, which 
can be compared to BM MSCs that lost their differentiation potential following 
few passages (Halfon, Abramov et al. 2011). Targeted exome sequencing of the 
AML samples revealed the presence of recurrent AML mutations in the following 
genes: DNMTT3A, EZH2, FLT3, IDH1, KRAS, NRAS, TET2, RUNX1, PTPN11, 
SF3B1, TP53 and U2AF1. Interestingly, none of these somatic mutations found 
in the AML cells were present in the BMS population after expansion. However, 
other studies have reported genetic aberrations of BMS (Huang, Basu et al. 2015, 
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Kim, Jekarl et al. 2015) but these mutations were distinct from the mutations in 
the malignant clone. The mechanisms of BMS specific mutations and their effect 
on AML development is still elusive and require further investigation. Regardless, 
BMS can serve as germline control to rule out the existence of germline genetic 
aberrations found in the AML clone. 
4.3 Paper III
The chromatin modulator protein the CCTC-binding factor (CTCF) plays an impor-
tant role in gene expression regulation by forming three-dimensional chromatin 
interactions (Fudenberg, Imakaev et al. 2016, Lu, Shan et al. 2016). CTCF binding 
can be affected by DNA methylation (Engel, West et al. 2004, Wang, Maurano 
et al. 2012), and thus, methylation could impact on chromatin structure through 
interfering with CTCF binding. CTCF is important for normal haematopoiesis 
(Torrano, Chernukhin et al. 2005, Splinter, Heath et al. 2006, Kim, Kim et al. 
2017) but its impact on tumour development remains unclear (Kemp, Moore et al. 
2014). In this study, we aimed to characterize CTCF occupancy in AML patient 
cells and its relation to DNA methylation, gene expression and chromatin struc-
ture. Our ChIP-seq data show that AML cells (AMLall) exhibit an aberrant gain in 
CTCF occupancy compared to normal CD34+ cells, especially in TET2 mutated 
AML (AMLTET2mut). In contrast, AML with mutated NPM1 (AMLNPM1mut) did not 
display strongly aberrant CTCF binding. The aberrantly bound CTCF binding sites 
(CBSs) in AMLTET2mut were mainly in the promoters. In contrast, aberrantly bound 
CBSs in general (AMLall) were enriched for enhancer locations. Motif analysis of 
differentially bound CTCF sites (DBCs) in AMLall showed enrichment of motifs 
for CEBPA, PU.1, ETS1 and RUNX1 transcription factors (TFs), which are TFs 
that have been implicated in the development of AML. Besides, motifs for DBCs 
specific for AMLTET2mut (AMLTET2mut vs. AMLTET2wt) were also enriched for other 
transcription factors such as KLF7 (Schuettpelz, Gopalan et al. 2012), HIC1 
(Britschgi, Jenal et al. 2008), SOX4 (Lu, Hsieh et al. 2017), BCL11A (Tao, Ma 
et al. 2016) and FOXH1 (Loizou, Banito et al. 2019) that have been proposed to 
play roles in haematopoiesis or leukaemia. To confirm the effect of CTCF on the 
binding to other TFs, we knockdown CTCF in K562 cells and performed ChIP-PCR 
for CTCF as well as RUNX1. ChIP-qPCR analysis of overlapping sites revealed a 
loss of binding of both CTCF and RUNX1 at several examined sites. To correlate 
changes in CTCF binding to changes chromatin organization, we also performed 
ChIP-Seq of selected histone marks (H3K18ac, H3Kt27ac, H3K4me1 and H2A.Z) 
in patients where data on CTCF binding was available. We found an increase in 
H3K27 acetylation, H3K18 acetylation and H3K4me1 at gained CTCF binding 
sites while some histone marks were decreased at lost DBCs in AML showing that 
increased CTCF binding is associated with increase in open chromatin and active 
transcription. DNA methylation and RNA-seq were performed on the same samples 
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to investigate the correlation between CTCF binding, DNA methylation and gene 
expression. The majority of CBSs were hypomethylated and CTCF binding anti-
correlated with DNA methylation. There was a seemingly paradoxical finding in 
AMLTET2mut with increased DNA methylation in TET2 mutated samples but still a 
gain of CTCF binding in the same samples. However, we found hypermethylation 
associated to TET2 mutations to occur dominantly outside of CTCF binding sites 
both in general and in the promoters. Also, the gain of CTCF binding in AMLTET2mut 
occurred at sites that are hypomethylated in both AMLTET2mut and AMLTET2wt, and 
thus, these sites do not change methylation status. Moreover, by integrating CTCF 
and gene expression, we found that gained DBCs in general was associated with 
upregluation of gene expression while loss of CTCF binding was associated with 
down-regulation of genes. However, the relation was dependent on the location 
of the aberrant CTCF binding where changes in promoters showed a clearer 
positive correlation while regions distant from promoters showed more anti-cor-
relation. In addition, upregulated genes that gained CBSs were hypomethylated, 
while downregulated genes that lost CBSs were hypermethylated. For instance, 
DOT1L, ZBTB7A, PDCD1 and FOSL2 were genes that showed both increase in 
CTCF binding and gene expression. To study the direct role of CTCF binding 
for gene expression, we knocked down CTCF in K562 cells and analysed CTCF 
binding and gene expression by ChIP-qPCR and qPCR, respectively. Following 
CTCF knockdown, DOT1L, ZBTB7A and PDCD1 exhibited loss of CTCF binding 
which was paralleled by downregulation of DOT1L and PDCD1. Thus, a change 
of CTCF binding can affect gene expression of nearby genes but likely requires 
other factors as well.  
We also treated AMLTET2mut with the demethylating drug azacytidine and investigated 
CTCF occupancy, DNA methylation and gene-expression in response to this drug. 
Azacytidine exposure induced DNA demethylation in AML cells and major changes 
in CTCF occupancy. Although sites were both gained and lost for CTCF, sites with 
a two-fold change were more common among gained sites. KLF6, a gene that has 
been shown to be dysregulated in AML (Matsumoto, Kubo et al. 2006, Adelman, 
Huang et al. 2019), was among the top genes that lost DNA methylation, gained 
CTCF binding, and was upregulated after azacytidine exposure. Finally, more 
than half of DBCs that were gained in AMLTET2mut in response to azacytidine were 
overlapping with CTCF binding sites occupied in normal CD34+ cells, implying 
a restoration CTCF occupancy to a status similar to normal cells. 
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5 CONCLUDING REMARKS
In study I, we found that leukemic cells protect themselves from APR-246 partly 
through expressing genes that counteract the oxidative stress caused by the 
drug, including activation of the NFE2L2/HMOX1 pathway. Indeed, knocking 
down NFE2L2 sensitized AML cells to the anti-leukaemic effects of APR-246. 
Additionally, disrupting NFE2L2/HMOX1 signalling by using PI3K and mTOR 
inhibitors significantly improved the cytotoxicity of APR-246. Thus, we suggest 
that such a combination therapy could increase efficacy of APR-246 and result in 
better treatment responses. 
In study II, the most significant finding is the ability to obtain germline DNA 
from previously vitally frozen diagnostic AML material. In this case, bone mar-
row stroma cells derived from non-haematopoietic cells constitute the source of 
germline DNA. This can be an attractive approach to obtain germline DNA for 
reliable genetic characterization of AML cases in clinical routine as well as for 
research purposes. 
In study III, we found that AML primary cells have an aberrant gain in CTCF 
occupancy mainly located in enhancers. AML with TET2 mutation appears to have 
a greater impact on CTCF occupancy with a gain, mainly located in promoters. 
It is not clear how AML cells exhibit increased CTCF binding mechanistically. 
Apparently, consequences on gene expression profiles were related to CTCF gain 
of binding where genes that gained CTCT at promoters were mainly upregulated. 
In addition, active chromatin represented by active histone marks were found 
around gained CTCF sites. This suggests that aberrant CTCF binding could con-
tribute to AML development by a change in chromatin organization that leads to 
aberrant gene expression patterns. However, to study the effect of AML specific 
changes in CTCF binding on the three-dimentional chromatin structure in more 
detail, studies using techniques such as HiC are warranted. 
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